Geron Corp.’s (GERN) “Neutral” Rating Reaffirmed at BTIG Research
Geron Corp. (NASDAQ:GERN)‘s stock had its “neutral” rating restated by research analysts at BTIG Research in a research report issued on Tuesday.
Several other research analysts have also commented on GERN. Piper Jaffray Cos. restated an “overweight” rating and set a $5.00 price target (down from $10.00) on shares of Geron Corp. in a research report on Tuesday, September 13th. FBR & Co lowered their price target on Geron Corp. from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, September 13th. Finally, Zacks Investment Research upgraded Geron Corp. from a “hold” rating to a “strong-buy” rating and set a $3.00 price target for the company in a research report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $5.00.
Shares of Geron Corp. (NASDAQ:GERN) traded up 2.50% on Tuesday, reaching $2.05. The company had a trading volume of 2,868,928 shares. Geron Corp. has a 12 month low of $1.84 and a 12 month high of $5.30. The firm has a market capitalization of $326.23 million, a PE ratio of 256.25 and a beta of 2.63. The firm’s 50 day moving average is $2.64 and its 200 day moving average is $2.80.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/geron-corp-s-gern-neutral-rating-reaffirmed-at-btig-research.html
Geron Corp. (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. Geron Corp. had a return on equity of 0.89% and a net margin of 3.39%. The business earned $0.21 million during the quarter, compared to analyst estimates of $0.38 million. During the same period last year, the business posted ($0.06) earnings per share. The company’s quarterly revenue was down 15.9% on a year-over-year basis. On average, equities research analysts expect that Geron Corp. will post ($0.23) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in GERN. IFP Advisors Inc boosted its stake in shares of Geron Corp. by 1.9% in the first quarter. IFP Advisors Inc now owns 35,090 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 650 shares during the last quarter. LPL Financial LLC boosted its stake in Geron Corp. by 81.0% in the first quarter. LPL Financial LLC now owns 35,750 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 16,000 shares in the last quarter. Bank of Montreal Can acquired a new stake in Geron Corp. during the second quarter worth $108,000. Bellevue Group AG acquired a new stake in Geron Corp. during the first quarter worth $131,000. Finally, TFS Capital LLC acquired a new stake in Geron Corp. during the second quarter worth $145,000. Institutional investors and hedge funds own 38.09% of the company’s stock.
About Geron Corp.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.
Receive News & Ratings for Geron Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron Corp. and related companies with MarketBeat.com's FREE daily email newsletter.